IP Library Granted Patent US 11,246,863
Granted Patent B2
US 11,246,863 · App. 16/060,873 · Granted Feb 15, 2022

Ciprofloxacin otic composition and kits and method for using same

Inventors: Scott H. Coleman (San Diego, CA); Wei-Cheng Liaw (San Diego, CA); Jerry Wroblewski (San Mateo, CA); Robert Savel (San Diego, CA)
Assignee: ALK-ABELLÓ, INC.
A61K31/496A61F15/001A61K9/00A61K9/0019A61K9/0046A61K47/10A61K47/34A61M5/002A61M5/1782A61M5/329A61M31/002A61P27/16A61B46/20A61F2007/108A61K9/14A61M2210/0668
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,246,863
App. No.
16/060,873
Granted
Feb 15, 2022
Kind
B2
Abstract

Disclosed herein are otic product kits for administration of a sterilized formulation. In some embodiments, the otic product kit comprises: an aseptic container containing the sterilized formulation; a syringe; and an administration needle connectable to the syringe, wherein the sterilized formulation comprising: from about 5.5 wt % to about 6.5 wt % multiparticulate ciprofloxacin; from about 15 wt % to about 17 wt % poloxamer 407; and water. Also disclosed herein are methods of preparing and administrating the sterilized formulation. In some embodiments, the method comprising (1) transferring the sterilized otic formulation from an aseptic container to a syringe through a preparation needle; (2) replacing the preparation needle with an administration needle; and (3) injecting the sterilized otic formulation from the syringe through the administration needle into the ear of a patient.

Claims (24)

1. An otic product kit for administration of a sterilized formulation, comprising:

an aseptic container containing the sterilized formulation;

a syringe; and

an administration needle connectable to the syringe,

wherein the administration needle is from 20 gauge to 24 gauge,

wherein the sterilized formulation comprising: from about 5.5 wt % to about 6.5 wt % multiparticulate ciprofloxacin; from about 15 wt % to about 17 wt % poloxamer 407; and water, and

wherein the multiparticulate ciprofloxacin has a D90 of from 10 μm to 35 μm.

2. The otic product kit of claim 1 , wherein the aseptic container is sealed with a cap.

3. The otic product kit of claim 2 , wherein the cap comprises a metal frame having a top wall and a side wall.

4. The otic product kit of claim 3 , wherein the metal frame is made of aluminum.

5. The otic product kit of claim 4 , wherein the cap further comprises a septum secured against the aseptic container by the aluminum frame.

6. The otic product kit of claim 1 , wherein the administration needle is flexible.

7. The otic product kit of claim 1 , wherein the administration needle has a blunt tip.

8. The otic product kit of claim 1 , wherein the administration needle has a length of from about 2 inches to about 3 inches.

9. The otic product kit of claim 1 , further comprising a preparation needle for transferring the sterilized otic formulation from the aseptic container to the syringe.

10. The otic product kit of claim 9 , wherein the preparation needle is from 18 gauge to 21 gauge.

11. The otic product kit of any one of claim 1 , further comprising an alcohol swab.

12. The otic product kit of any one of claim 1 , further comprising an ice pack.

13. The otic product kit of any one of claim 1 , further comprising a drape.

14. The otic product kit of any one of claim 1 , wherein the sterilized formulation provides sustained release of a therapeutically effective amount of ciprofloxacin into the ear for a period of at least 5 days after a single administration.

15. The otic product kit of any one of claim 1 , where the sterilized formulation has a pH of from about 7.0 to about 8.0.

16. The otic product kit of any one of claim 1 , where the sterilized formulation has an osmolarity of from about 270 mOsm/L to about 320 mOsm/L.

17. The otic product kit of claim 1 , wherein the administration needle is not straight.

18. The otic product kit of claim 1 , wherein the administration needle comprises at least one bend along longitudinal axis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2021
From: OTONOMY, INC.
To: ALK-ABELLÓ, INC.
Reel/Frame 056857/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2019
From: COLEMAN, SCOTT H.; LIAW, WEI-CHENG; SAVEL, ROBERT; WROBLEWSKI, JERRY
To: OTONOMY, INC.
Reel/Frame 049730/0537 →
Continuity (3)
Provisional Application 62302724 · Mar 2, 2016
Provisional Application 62266537 · Dec 11, 2015
Related Publication 20190000839A1 · Jan 3, 2019